Some limitations of our study were the fact that we did not observe any case of natalizumab-induced PML and that we did not evaluate the specificity of CD8 subsets, which accumulate in peripheral blood after natalizumab treatment. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.